CollPlant, a clinical-stage biotech focused on regenerative medicine for tissue repair, filed on Friday with the SEC to raise up to $25 million in an initial public offering.
The Ness-Ziona, Israel-based company was founded in 2004. It plans to list on the Nasdaq under the symbol CLGN. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
